花园生物 reported revenue of ¥0.69B for the period ended 2026-06-30, +8.9% year on year. Net income was ¥0.13B, a 19.1% net margin on a 45.2% gross margin. The largest revenue line is 维生素产品 at 52% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.69B | +8.9% |
| Gross profit | ¥0.31B | — |
| Operating income | ¥0.15B | — |
| Net income | ¥0.13B | -18.3% |
| Gross margin | 45.2% | Net margin 19.1% |
| Revenue Q/Q | +50.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 维生素产品 | ¥0.36B | 51.9% |
| 胆固醇及其衍生品 | ¥0.18B | 25.8% |
| 药品 | ¥0.14B | 20.9% |
| 其他 | ¥0.01B | 1.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.38B | 54.8% |
| R&D | ¥0.05B | 6.6% |
| SG&A | ¥0.09B | 13.2% |
| Tax & other | ¥0.02B | 2.5% |
| Item | Amount |
|---|---|
| Total assets | ¥5.93B |
| Total liabilities | ¥2.36B |
| Shareholders' equity | ¥3.58B |
| Equity / assets | 60.3% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | 148% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
宝色股份 ・ 汉宇集团 ・ 博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies